@FiercePharma: Bayer's OTC growth march continues with pickup of China's Dihon. Story | Follow @FiercePharma
@TracyStaton: If you can't get enough of the transition at Novartis: Gist: Shareholders speak at AGM; they like the pay cuts. Story (sub. req.) | Follow @TracyStaton
@EricPFierce: No sooner does Commish Hamburg return from India than the FDA reveals a new warning letter about data faking there. More | Follow @EricPFierce
@CarlyHFierce: Via FierceBiotech: Regeneron's Schleifer hits the $1B mark, but his biotech is just getting started. Article | Follow @CarlyHFierce
> After thwarting a takeover attempt by Chilean drugmaker CFR Pharmaceuticals, South Africa-based Adcock Ingram's rebel shareholders managed to vault Bidvest CEO Brian Joffe into the drugmaker's chairman's role. Report
> Pittsburgh-based generics maker Mylan ($MYL) predicted its 2014 revenue would rise by as much as 16%, to $7.8 billion to $8.2 billion, with CEO Heather Bresch hinting at a forthcoming buyout. Release
> Malvern, PA-based Endo Health Solutions ($ENDP) shareholders approved its $1.6 billion buyout of the Canadian drugmaker Paladin Labs. Release
> Since the Generic Drug User Fee Act went into effect, the FDA's approval process has grown murky, with less communication between the agency and manufacturers, Momenta Pharmaceuticals ($MNTA) CEO and General Pharmaceutical Association Chairman Craig Wheeler says. Report
> Bedford, MA-based Anika Therapeutics ($ANIK) won FDA approval for its injectable drug Monovisc to treat osteoarthritis in the knee. Report
> The Spanish blood products maker Grifols posted a 35% increase in net profit to €345.6 million, or about $472 million, on revenue of €2.74 billion. Report
@FierceMedDev: A proposed reform of the tax code would also repeal the 2.3% medical device tax. Naturally, the industry likes. Story | Follow @FierceMedDev
@MarkHFierce: New research suggests that pacers and the like are safe for CT scans, contrary to FDA fears. Item | Follow @MarkHFierce
@MichaelGFierce: From this week's FierceDrugDelivery report: Inner-ear delivery device sends drugs out, draws fluid in. More | Follow @MichaelGFierce
@EmilyWFierce: FDA calls for first major redrawing of food labels since the '90s, putting calorie counts front and center. Article | Follow @EmilyWFierce
> Researchers chide FDA: Pacemaker patients need not fear a CT scan. News
> FDA eyes March for Staar ocular implant review. Story
> Covidien closes its $860M Given Imaging buyout. More
Biotech News
@FierceBiotech: Radius Health looks to catch the IPO wave with $86M pitch. News | Follow @FierceBiotech
@JohnCFierce: Generics manufacturing--the "Wild West." I'm telling you, this is a scandal in the making. Piece via Bloomberg | Follow @JohnCFierce
@DamianFierce: Analyst: Merck's PD-1 promise could heap $5B on 2020 revenue. Story | Follow @DamianFierce
@EmilyMFierce: NIH makes new database on age-related diseases available to researchers. Item | Follow @EmilyMFierce
> Regeneron's Schleifer hits the $1B mark, but his biotech is just getting started. More
> Longtime R&D critic Valeant finds itself with a growing pipeline, and a setback. Story
Pharma Manufacturing News
> Mylan earnings point to reason for Agila deal. Report
> Bayer expands production in China by bagging Dihon. News
> Pfizer gets past shortage of hypothyroid drug Levoxyl. Story
> Critics call for harsher treatment of foreign drugmakers who sell faulty drugs. Article
> Doc goes to jail for lying about foreign-sourced Botox. Story
> AstraZeneca's Delaware campus sold to JPMorgan. Brief
Vaccines News
> H1N1's dominance this flu season makes quadrivalent vaccines' broader protection moot. Story
> Pfizer reports its huge trial of Prevnar has met its primary and secondary goals. News
> CDC is 'not unduly alarmed' by cases of a polio-like illness in California. Story
> Data mining study links seasonal flu vaccine to 24% drop in likelihood of stroke. Research
> MMR vaccine linked to fall in respiratory-related hospitalizations. Investigation
> Taiwan's Adimmune targets June start for mass production of bird flu vaccine. Brief
Editor's Note
> A story in Wednesday's issue of FiercePharma mis-stated the death rate in one of two Pradaxa studies. It was 19.5 per 10,000, not 19.5% per 10,000.
> A story in Tuesday's issue of FiercePharma mistakenly named GlaxoSmithKline as a maker of Testim. GSK formerly co-marketed the drug with Auxilium and never produced it.
And Finally... The FDA proposes new food labels that will highlight added sugars and include more realistic serving sizes. Report